What Are PARPs?
PARPs (poly-ADP-ribose polymerases) are a family of 17 NAD⁺-dependent enzymes that catalyze the transfer of ADP-ribose from NAD⁺ to target molecules—primarily proteins—in a process called ADP-ribosylation. 1
Core Biochemical Function
PARPs function as transferases that modify proteins through two distinct mechanisms:
- Poly(ADP-ribosyl)ation (PARylation): A few PARPs create chains of ADP-ribose polymers on target proteins
- Mono(ADP-ribosyl)ation (MARylation): Most PARPs transfer only a single ADP-ribose unit 2
The enzymatic reaction consumes NAD⁺ as a cofactor, cleaving it to transfer the ADP-ribose moiety while releasing nicotinamide 1.
Structural Classification
The PARP family divides into functional subcategories based on domain architecture 2:
- DNA-dependent PARPs (PARP1, PARP2): Activated by DNA strand breaks
- Tankyrases (PARP5a/5b): Regulate telomere maintenance and Wnt signaling
- CCCH-type PARPs: Contain zinc finger domains
- MacroPARPs: Possess macrodomains that recognize ADP-ribose
- Atypical PARPs: Diverse structural features
Primary Biological Roles
DNA Repair: PARP1 and PARP2 detect DNA damage and orchestrate base excision repair and single-strand break repair pathways 3, 4. This function forms the mechanistic basis for PARP inhibitor therapy in cancer—tumors with homologous recombination defects (particularly BRCA mutations) become dependent on PARP-mediated repair and die when it is blocked 5.
Chromatin Regulation: PARPs modulate chromatin structure and gene transcription through protein modification 3.
Telomere Maintenance: Tankyrase 1 (PARP5a) enhances telomere elongation by telomerase 6.
Metabolic Regulation: PARPs influence cellular metabolism through NAD⁺ consumption and signaling pathway modulation 4.
Immune Signaling: PARP7, PARP11, and PARP14 regulate innate immune responses in both tumor cells and tumor-associated immune cells 7. Notably, some PARP1 inhibitors paradoxically activate innate immune signaling in DNA repair-deficient cancer cells 7.
Clinical Relevance
The therapeutic exploitation of PARPs centers on synthetic lethality—cancer cells with defective homologous recombination (BRCA1/2 mutations) cannot survive without functional PARP-mediated repair 6. This principle has led to FDA approval of multiple PARP inhibitors (olaparib, niraparib, rucaparib) for ovarian, breast, pancreatic, and prostate cancers 5.
Beyond oncology, PARP dysregulation contributes to neurodegenerative diseases, cardiovascular disorders, inflammatory conditions, and viral infections, though therapeutic applications in these areas remain less developed 2.
Emerging Insights
Recent discoveries reveal that PARPs can ADP-ribosylate not only proteins but also nucleic acids 8. Additionally, the identification of ADP-ribosyl hydrolases (particularly PARG) that reverse these modifications has expanded understanding of ADP-ribosylation as a dynamic regulatory system 9.